Form 8-K - Current report:
SEC Accession No. 0001193125-25-036794
Filing Date
2025-02-26
Accepted
2025-02-26 16:30:31
Documents
13
Period of Report
2025-02-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d891467d8k.htm   iXBRL 8-K 26045
  Complete submission text file 0001193125-25-036794.txt   147983

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250224.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250224_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250224_pre.xml EX-101.PRE 11251
15 EXTRACTED XBRL INSTANCE DOCUMENT d891467d8k_htm.xml XML 3655
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 25670631
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)